FATE logo

Fate Therapeutics Inc. (FATE)

$1.02

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on FATE

Market cap

$124000130

EPS

-1.03

P/E ratio

--

Price to sales

40.24

Dividend yield

--

Beta

2.65347

Price on FATE

Previous close

$1.14

Today's open

$1.10

Day's range

$1.01 - $1.13

52 week range

$0.95 - $3.23

Profile about FATE

CEO

J. Scott Wolchko

Employees

161

Headquarters

San Diego, CA

Exchange

NASDAQ Global Market

Shares outstanding

121568755

Issue type

Common Stock

FATE industries and sectors

Healthcare

Biotechnology & Life Sciences

News on FATE

Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy

Updated safety data of 36 patients treated with FT819 across three regimens and four autoimmune disease indications with no dose-limiting toxicities continues to be favorable 100% (3 of 3) of extrarenal lupus patients treated with FT819 without the use of conditioning chemotherapy experienced measurable responses with two patients achieving the Definition of Remission in Systemic Lupus Erythematosus (DORIS) and the third achieving Lupus Low Disease Activity State (LLDAS) First patient treated with two doses of FT819 achieved a significant reduction of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) by 8 points at Month 1, achieving LLDAS by Month 2, which was sustained at Month 3 New preclinical data show FT839 eliminates a broad spectrum of activated immune cells in models of rheumatoid arthritis supporting immune cell reset in multicellular disease; COMPLETE™ Phase 1/2 basket trial open for enrollment SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative and broadly accessible pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that updated clinical data for FT819, together with translational and patient-perspective data, as well as preclinical data for FT839, are being presented in four presentations at the American College of Rheumatology (ACR) Convergence 2026, held November 6–11 in Orlando, Florida. "Our recent clinical data presented at ACR continues to show that FT819 can be delivered in a safe and effective manner that fits into routine rheumatology care," said Bob Valamehr, Ph.D.

news source

GlobeNewsWire • Nov 10, 2026

news preview

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be favorable, further supporting RECLAIM-LN

news source

GlobeNewsWire • Nov 5, 2026

news preview

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative and broadly accessible pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on November 2, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 300,000 shares of the Company's common stock at an exercise price per share of $2.01, which was the closing price per share of the Company's common stock as reported by NASDAQ on November 2, 2026, and (ii) restricted stock units (RSUs) representing 87,000 shares of its common stock to two newly-hired non-executive employees, including the newly-hired employee receiving the non-qualified stock options referenced above. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

news source

GlobeNewsWire • Nov 3, 2026

news preview

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with approximately 50% mean reduction in proteinuria Encouraging safety profile with no dose-limiting toxicities, high-grade CRS, ICANS, GvHD or IEC-HS in autoimmune patients treated with a single dose of FT819; low incidences of infection and cytopenia were also observed Clinical data reinforces the patient value of the ongoing RECLAIM-LN, a Phase 2 potentially registrational study of FT819 in refractory, moderate-to-severe SLE with LN FT819 continues to offer a unique product profile with the simplicity to dose CAR T-cell therapy on-demand in the community setting SAN DIEGO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative and broadly accessible pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced updated Phase 1 clinical data for FT819, its off-the-shelf, available on-demand, anti-CD19 CAR T-cell product candidate, in patients with systemic lupus erythematosus (SLE) with lupus nephritis (LN) were featured in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026, held October 22–25 in Denver, Colorado. The oral presentation, "Off-the-Shelf Anti-CD19 Chimeric Antigen Receptor (CAR)-T Cell Therapy with Less-Intensive Fludarabine-Free Conditioning in Lupus Nephritis: Phase 1 Safety and Efficacy," was presented on October 24, 2026, by Jonathan D.

news source

GlobeNewsWire • Oct 26, 2026

news preview

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the fourth quarter of 2026.

news source

GlobeNewsWire • Oct 1, 2026

news preview

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis

news source

GlobeNewsWire • Sep 25, 2026

news preview

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at the American College of Rheumatology (ACR) Convergence 2026, being held November 6-11 in Orlando, Florida.

news source

GlobeNewsWire • Sep 16, 2026

news preview

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced clinical data from its off-the-shelf anti-CD19 CAR T-cell product candidate FT819, and pre-clinical data from its off-the-shelf anti-CD19 and CD38 CAR T-cell product candidate FT839 will be featured at the Congress of Clinical Rheumatology West (CCR – West) meeting, being held in Huntington Beach, CA on September 17-20, 2026.

news source

GlobeNewsWire • Sep 9, 2026

news preview

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference, being held September 9–12, 2026 in New York, NY.

news source

GlobeNewsWire • Sep 3, 2026

news preview

Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead

Fate Therapeutics has initiated the phase 2 RECLAIM-LN trial of FT819 in lupus nephritis, dosing the first patient in an outpatient setting. FATE plans to open 20 trial sites by the end of 2026 and expects interim analysis data from multiple patients in H2'27, potentially accelerating enrollment. Phase 1 data for FT819 showed reductions in disease activity in systemic lupus erythematosus, including in patients with lupus nephritis.

news source

Seeking Alpha • Sep 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Fate Therapeutics Inc.

Open an M1 investment account to buy and sell Fate Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in FATE on M1